MAPT and Alzheimer disease: We found that total participants (β = -0.1548, p = 0.0096) (Table 2) and AD patients (β = -0.3961, p = 0.0115) with C allele (CC, TC) showed a slower rate of change in CSF T-tau levels than TT allele carriers after controlling for age, gender, education and APOEε4 status (Figure 1B), but no associations were found with CSF Aβ1-42 levels, CSF P-tau levels, neuroimaging biomarkers and cognitive function (Table 2 and Supplementary Table 1).